Although this study is limited by its lack of access to laboratory measures of CKD and a short period of observation of SGLT-2 inhibitor utilisation following its approval for full-reimbursement, these results highlight an urgent need for improved kidney-protective treatment to improve patient outcomes in CKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.